### ORIGINAL PAPER

# WILEY

# Visit-to-visit blood pressure variability is associated with arterial stiffness in Chinese adults: A prospective analysis

Yuwen Zhang MD, PhD<sup>1,2</sup> | Lizhan Bie MD, PhD<sup>1,2</sup> | Mian Li MD, PhD<sup>1,2</sup> | Tiange Wang MD, PhD<sup>1,2</sup> | Min Xu MD, PhD<sup>1,2</sup> | Jieli Lu MD, PhD<sup>1,2</sup> | Shuangyuan Wang PhD<sup>1,2</sup> | Jie Zhang MD, PhD<sup>1,2</sup> | Yufang Bi MD, PhD<sup>1,2</sup> | Weiqing Wang MD, PhD<sup>1,2</sup> | Guang Ning MD, PhD<sup>1,2</sup> | Yuhong Chen MD, PhD<sup>1,2</sup> | Yu Xu MD, PhD<sup>1,2</sup>

<sup>1</sup>Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

<sup>2</sup>Shanghai National Clinical Research Center for metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai National Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

#### Correspondence

Yuhong Chen, MD, PhD and Yu Xu, MD, PhD, Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Rui Jin 2nd Road, Shanghai, China.

Email: chenyh70@126.com and jane. yuxu@gmail.com

Funding informationThis work was supported by the grants from the National Natural Science Foundation of China (81870560, 81870604, and 8151128019), the National Key R&D Program of China (2017YFC1310700, 2016YFC1304904, and 2016YFC1305600), the Shanghai Municipal Government (18411951800), the Shanghai Shenkang Hospital Development Center (SHDC12019101), the Shanghai Jiaotong University School of Medicine (DLY201801), and the Ruijin Hospital (2018CR002) and the Innovative Research Team of High-level Local Universities in Shanghai.

### Abstract

Blood pressure (BP) variability may have its effect on the development of vascular disease. The authors aimed to examine the association between the visit-to-visit variability (VVV) of BP and arterial stiffness in Chinese adults. The authors included 1407 participants from a prospective cohort study of community residents who were ≥40 years, without a history of myocardial infarction or stroke, and with data at the baseline, the second and the third visits in 2008, 2009, and 2013. The VVV of BP was defined as the standard deviation (SD), the coefficient of variation (CV), the average successive variability (ASV), and the variability independent of the mean (VIM) in BP levels at the 3 visits. Arterial stiffness was measured by brachial-ankle pulse wave velocity (ba-PWV) at the 2nd and the 3rd visits. Levels of ba-PWV change and the occurrence of an elevated ba-PWV increased significantly in the highest tertile of VVV measures of systolic BP (SBP) and pulse pressure (PP) compared with the lowest tertile, respectively. The multivariable regression analysis revealed that VVV measures of SBP and PP were significantly associated with levels of ba-PWV change and the risks of developing an elevated ba-PWV. The odds ratios (ORs) and 95% confidence intervals (CIs) for the risk were 2.12 (1.57-3.12) and 1.92 (1.38-2.68) in participants with the highest versus the lowest tertile of SBP-SD and PP-SD, respectively. No significant association was found for diastolic BP variability measures. The increased long-term variabilities of SBP and PP were associated with an increased risk of arterial stiffness.

Yuwen Zhang and Lizhan Bie contributed equally to this work.

[Correction added on January 30, 2021, after first online publication: The statement "Yuhong Chen and Yu Xu contributed equally to this work" has been changed to "Yuwen Zhang and Lizhan Bie contributed equally to this work".]

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. © 2021 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC.

# 1 | INTRODUCTION

Blood pressure (BP) level is strongly associated with stroke, myocardial infarction (MI), and mortality.<sup>1-3</sup> Normal BP, defined as the mean of multiple BP measurements over a period of time, is the most important in the pathophysiology of vascular disease and the basis for recommending optimal BP targets.<sup>1,4</sup> However, average BP cannot fully capture BP-related vascular risk, and changes in BP level have been shown to associate with cardiovascular (CV) events and mortality.<sup>5-7</sup> Although BP variability (BPV) is physiological, it may represent an adaptive humoral and neural response to environmental, behavioral, and emotional stimuli in daily life or may be increased or decreased by antihypertensive treatment.<sup>8</sup> Recently, increasing attention has been paid to the value of visit-to-visit BPV.<sup>9-16</sup>

Visit-to-visit BPV, considered as a long-term BPV, is an intraindividual variation in BP over different clinical visits.<sup>17</sup> Elevated BPV may reflect arterial stiffness and baroreceptor dysfunction, which may be associated with endothelial injury and atherosclerosis and may finally lead to cardiovascular events.<sup>18-21</sup>

Previous studies have mostly focused on the visit-to-visit variability (VVV) of systolic BP (SBP) as the long-term BPV and these studies were conducted in various patient populations such as patients with hypertension,  $^{9,12,17}$  patients with diabetes,  $^{10,22-24}$  and patients with a history of other CV disease (CVD) risk factors,  $^{6,25-28}$ from which findings may not be generalizable to other populations. Moreover, these studies focused on the associations of BPV with clinical CVD events and all-cause mortality. Few studies have investigated the associations of long-term BPV with subclinical atherosclerosis in a general population.<sup>29</sup> Therefore, we used data from a community-based cohort study with several times of BP measurements within years to examine the association between VVV of BP and arterial stiffness measured by brachial-ankle pulse wave velocity (ba-PWV) among Chinese adults aged ≥40 years.

## 2 | METHODS

### 2.1 | Study population

Study participants were from an ongoing prospective cohort study, the design of which has been published previously.<sup>30</sup> Briefly, participants were enrolled from a suburban community in Shanghai, China, and underwent 3 examination visits. At the baseline visit (June and July 2008), 10 185 community residents over 40 years or older participated in a screening examination. The fasting plasma glucose (FPG) levels were measured, and participants were divided into three groups accordingly<sup>31</sup>: normal glucose regulation (NGR), with FPG level less than 100 mg/dl and never having diabetes; impaired glucose regulation (IGR), with FPG level of 100 to 125 mg/dl and never having diabetes; and diabetes, with FPG level of 126 mg/dl or greater or a history of diabetes. In the 2nd visit (June through August 2009), participants were randomly selected from the three groups in a ratio of 1.0 (diabetes) to 1.2 (IGR) to 1.44 (NGR). We selected more people with lower blood glucose

levels because they might have a lower participation rate than those with higher blood glucose levels. All the selected participants received a comprehensive examination including BP measurement and evaluation of arterial stiffness using ba-PWV. In the 3rd visit (March through May 2013), participants who participated in the 2nd visit were invited to have re-evaluations of BP and ba-PWV. The participation rate in the 3rd visit of those seen at visit 2 was 71.9% (2883/4012).

For the current study, participants with a history of myocardial infarction or stroke prior to the baseline visit (n = 139), participants with missing data for BP at any of the 3 visits (n = 54), with missing data for ba-PWV at the 2nd or the 3rd visit (n = 64), with antihypertensive medications at any of the 3 visits (n = 751), or with ba-PWV level within the highest quartile ( $\geq 1618$  cm/s) at the 2nd visit (n = 468) were excluded. Eventually, 1407 participants were included for the current analysis (Figure 1).

The study protocol was approved by the Institutional Review Board of Ruijin Hospital, Shanghai Jiaotong University School of Medicine. All study participants provided written informed consent.

### 2.2 | Data collection

Detailed information such as demographic and lifestyle factors, medical history, and medication use was obtained through a standard questionnaire administered by trained physicians. The International Physical Activity Questionnaire was used to collect information on participants' physical activities and being physically active was defined by the highest tertile of metabolic equivalent-hours per week.<sup>32</sup> When measuring their height and weight, participants wore lightweight clothes without shoes. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Waist circumference (WC) was measured at the level of the umbilicus. BP and heart rate (HR) were measured three times consecutively with 1-min intervals after resting for at least 5 min using an automated electronic device (OMRON Model HEM-752, Omron Company). The mean value of the three measurements was used in analysis. Pulse pressure (PP) was defined as SBP-diastolic BP (DBP). Participants were instructed to avoid alcohol, tea, coffee, and exercise 30 min before BP measurements.

Participants were asked to fast overnight for at least 10 h, and the venous blood samples were collected in the early morning. Plasma concentrations of fasting glucose, serum concentrations of triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), and low-density lipoprotein cholesterol (LDL-c) were measured by an autoanalyzer (ADVIA-1650 Chemistry System, Bayer).

### 2.3 | Measures of visit-to-visit BPV

Using BP levels at each of the three visits, we calculated the VVV of BP using (1) the standard deviation (SD), (2) the coefficient of



FIGURE 1 Flowchart of the study population

variation (CV), (3) the average successive variability (ASV) defined as the average absolute difference between successive values, and (4) the variability independent of the mean (VIM), which was calculated as 100<sup>\*</sup>SD/mean<sup> $\beta$ </sup>, where  $\beta$  is the regression coefficient based on natural logarithm of SD on natural logarithm of mean. All these four metrics have been described in previous studies.<sup>33-35</sup>

### 2.4 | Measurement of ba-PWV

Participants were required to take 15-30 min of rest before ba-PWV examination. Ba-PWV was measured using the Colin VP-1000 (Model BP203RPEII, form PWV/ABI; OMRON Colin Medical Instruments) as reported previously.<sup>36</sup> Measured with cuffs placed on the upper arms and the ankles, pulse waves were obtained simultaneously from the brachial and tibial arteries. The greater value of the right and the left ba-PWV was used for analysis.

An elevated ba-PWV was defined as a ba-PWV  $\ge$  1618 cm/s, which was the upper quartile of ba-PWV at the 2nd visit. Ba-PWV change was calculated by abstracting ba-PWV at the 2nd visit from ba-PWV at the 3rd visit. The ratio of ba-PWV change was calculated by dividing ba-PWV change by ba-PWV level at the 2nd visit. The occurrence of an elevated ba-PWV was defined as the proportion of elevated ba-PWV (ba-PWV  $\ge$  1618 cm/s) at the 3rd visit.

804

### 2.5 | Statistical analysis

General characteristics were demonstrated in total participants and according to SBP-SD tertiles. Continuous variables were presented as mean  $\pm$  SD for normally distributed variables or medians (interquartile ranges) for the skewed variables. We log<sub>10</sub>-transformed TG to achieve a normal distribution. All the categorical variables were presented as numbers and proportions. We used the ANOVA test to compare continuous variables and the chi-square test to compare categorical variables.

Multiple linear regression models were used to explore the associations of each BPV measure (SD, CV, ASV, and VIM) with the ba-PWV change and ratio of ba-PWV change adjusted for covariates. Four models were used. Model 1 was adjusted for age and sex. Model 2 was further adjusted for education, current smoking, current drinking, and physical activity. Model 3 was further adjusted for baseline WC, DBP/SBP/- (for SBP variability/DBP variability/PP variability, respectively), FPG, log<sub>10</sub>TG, LDL-c, and HR. Model 4 additionally accounted for average SBP/DBP/PP of the 3 visits (for SBP variability/DBP variability/PP variability, respectively) and ba-PWV at the 2nd visit.

We also used multivariable logistic regression models to evaluate the associations of each BPV measure (SD, CV, ASV, and VIM) with elevated ba-PWV. Tertiles of each BPV measure were used in the models with the lowest tertile as the reference. Similar models were used as the linear regression models except that model 4 did not adjust for ba-PWV at the 2nd visit. Adjusted odds ratio (OR) and 95% confidence interval (CI) were calculated.

Subgroup analyses were performed in participants defined by age, sex, BMI, smoking status, drinking status, diabetes status, and hypertension status. We assessed if there were interactions by adding interaction terms in the adjusted models.

All analyses were performed with the use of SPSS software version 22.0 (SPSS Inc). Significance tests were two-tailed, with a p value < .05 considered as statistically significant.

## 3 | RESULTS

# 3.1 | Clinical characteristics of the study population

The baseline demographic and clinical characteristics of the participants across tertiles of SBP-SD are presented in Table 1. Of the 1407 participants included in the study, mean age was  $54.7 \pm 8.0$  years and 36.3% (n = 511) were men. Participants in the highest tertile of SBP-SD were more likely to be older. They had higher levels of baseline WC, PP, FPG, LDL-c, average SBP, DBP, and PP and a lower level of baseline HR.

### 3.2 | Visit-to-visit BPV and ba-PWV

The ba-PWV change, the ratio of ba-PWV change and the occurrence of an elevated ba-PWV across the SBP, DBP and PP VVV tertiles are shown in Figure 2 and Supplemental Figures S1–S3. They increased significantly across the tertiles of SBP and PP VVV measures. Less evident increase was found across the tertiles of DBP VVV measures.

The multiple linear regression analysis showed that measures of SBP and PP VVV were significantly and independently associated with the ba-PWV change and the ratio of ba-PWV change even after full adjustment for confounders. The associations for DBP VVV measures were not significant or borderline significant (Table 2 and Supplemental Table S1).

We further analyzed the associations between visit-to-visit BPV and the occurrence of an elevated ba-PWV in multivariable logistic regression models. As shown in Table 3 and Supplemental Table S2, when visit-to-visit BPV was examined as a continuous variable in the fully adjusted model (model 4), higher VVV of SBP was significantly associated with an increased risk of developing elevated ba-PWV. Greater VVV of PP was also significantly associated with an increased occurrence of elevated ba-PWV, while no significant association was found for VVV of DBP and the occurrence of elevated ba-PWV. Participants with the highest tertile of SBP-SD had a 1.22-fold increased risk of developing elevated ba-PWV compared with participants with the lowest tertile of SBP-SD after full adjustment (model 4; OR 2.22 [95% CI 1.57-3.12]). The highest tertile of PP-SD conferred an 92% increased risk of developing elevated ba-PWV compared with the lowest tertile of PP-SD (OR 1.92 [95% CI 1.38-2.68]). However, no significant increase in the occurrence of an elevated ba-PWV was found in participants with the highest tertile of DBP-SD compared with those with the lowest tertile of DBP-SD (OR 1.11 [95% CI 0.81-1.53]) (Table 4). Similar results were observed for other measures of VVV (Supplemental Table S3). In addition, we have conducted a sensitivity analysis using the upper quintile of ba-PWV at the 2nd visit (ba-PWV ≥ 1672 cm/s) as the cut-point of elevated ba-PWV and re-did the multivariable logistic regression analysis. Similar findings were observed (Supplemental Tables S4 and S5).

Results for subgroup analysis are shown in Figure 3 and Supplemental Figures S4–S6. Sex, diabetes status, and hypertension status all significantly interacted with SBP VVV measures in association with the risk of developing an elevated ba-PWV, whereas hypertension status had significant interactions with DBP VVV measures and PP VVV measures in association with arterial stiffness (all *p* for interaction < .05). BP VVV measures were associated with the development of an elevated ba-PWV more closely in participants without hypertension compared with those with hypertension.

# 4 | DISCUSSION

In the current study, we observed a significant association between the increased VVV of SBP or PP assessed by four indicators (SD, CV, ASV, and VIM) and increased arterial stiffness measured by ba-PWV. The direction and the magnitude of these associations were roughly consistent across measures of SBP or PP variability, and they remained significant even after adjustment for average SBP or average

| TABLE 1 | Baseline | characteristics | of study | participants b  | v tertiles | of SBP-SD |
|---------|----------|-----------------|----------|-----------------|------------|-----------|
| INDEE I | Duschine | characteristics | or study | pur ticipunto b | y terthes  | 0130130   |

806

WILEY

|                                              |                    |                    | Т2                    |                      | р     |
|----------------------------------------------|--------------------|--------------------|-----------------------|----------------------|-------|
| Characteristics                              | Total              | T1 (<6.17 mmHg)    | (6.17–10.60 mmHg)     | T3 (>10.60 mmHg)     | value |
| Participants, n                              | 1407               | 468                | 469                   | 470                  | /     |
| SBP-SD, mmHg                                 | 8.26 (5.21–12.03)  | 4.16 (2.81-5.21)   | 8.26 (7.20-9.49)      | 14.02 (12.03–16.85)  | /     |
| Age, years                                   | 54.7 ± 8.0         | 53.4 ± 7.4         | 54.2 ± 7.9            | 56.4 ± 8.3           | <.001 |
| Men, n (%)                                   | 511 (36.3)         | 178 (38.0)         | 166 (35.5)            | 166 (35.3)           | .637  |
| Body mass index, kg/m <sup>2</sup>           | $24.8 \pm 3.5$     | 24.7 ± 3.4         | 24.7 ± 3.6            | 25.1 ± 3.6           | .083  |
| Waist circumference, cm                      | 83.1 ± 9.7         | 82.7 ± 9.8         | 82.6 ± 9.8            | 84.1 ± 9.4           | .020  |
| High school education or above, <i>n</i> (%) | 433 (30.8)         | 155 (33.1)         | 147 (31.3)            | 131 (27.9)           | .239  |
| Life style factors, n (%)                    |                    |                    |                       |                      |       |
| Current smoking                              | 363 (25.8)         | 108 (23.1)         | 127 (27.1)            | 127 (27.0)           | .256  |
| Current drinking                             | 233 (16.6)         | 75 (16.0)          | 83 (17.7)             | 75 (16.0)            | .719  |
| Physically active                            | 462 (32.8)         | 148 (31.6)         | 161 (34.4)            | 152 (32.3)           | .612  |
| Heart rate, beats per minute                 | 76.3 ± 10.1        | 77.2 ± 10.1        | 76.5 ± 9.9            | 75.3 ± 10.4          | .016  |
| Blood pressure, mmHg                         |                    |                    |                       |                      |       |
| Systolic blood pressure                      | 123.1 ± 16.2       | 122.2 ± 14.7       | 123.1 ± 15.2          | 124.1 ± 18.5         | .181  |
| Diastolic blood pressure                     | 76.6 ± 9.4         | 76.8 ± 9.0         | 76.6 ± 9.3            | 76.6 ± 9.9           | .915  |
| Pulse pressure                               | 46.5 ± 11.9        | 45.4 ± 10.3        | 46.5 ± 11.5           | 47.6 ± 13.5          | .020  |
| Average blood pressure <sup>*</sup> , mmHg   |                    |                    |                       |                      |       |
| Systolic blood pressure                      | 127.3 ± 14.5       | 123.2 ± 14.0       | 126.8 ± 13.3          | 131.8 ± 14.7         | <.001 |
| Diastolic blood pressure                     | 76.4 ± 8.2         | 75.6 ± 8.3         | 76.1 ± 8.1            | 77.5 ± 8.0           | .001  |
| Pulse pressure                               | 50.9 ± 11.3        | 47.7 ± 10.2        | 50.7 ± 10.7           | 54.3 ± 12.0          | <.001 |
| Fasting plasma glucose, mg/dl                | 98.9 ± 31.0        | 96.0 ± 24.5        | 98.6 ± 31.9           | 102.0 ± 35.5         | .011  |
| Lipid profile, mg/dl                         |                    |                    |                       |                      |       |
| Triglycerides                                | 117.0 (82.4–171.9) | 120.1 (79.7–172.5) | 110.75 (81.51–162.14) | 118.3 (85.06–181.63) | .202  |
| Total cholesterol                            | 196.5 ± 36.1       | 194.1 ± 33.9       | 196.9 ± 39.3          | 198.5 ± 34.9         | .172  |
| High-density lipoprotein cholesterol         | 54.5 ± 11.5        | 54.5 ± 11.8        | 55.1 ± 11.6           | 53.9 ± 11.2          | .244  |
| Low-density lipoprotein cholesterol          | 94.0 ± 25.6        | 92.8 ± 25.1        | 92.8 ± 26.3           | 96.5 ± 25.3          | .033  |
| Diabetes, n (%)                              | 243 (17.3)         | 63 (13.5)          | 86 (18.3)             | 63 (13.5)            | .023  |
| Hypertension, n (%)                          | 366 (26.0)         | 113 (24.1)         | 112 (23.9)            | 141 (30.0)           | .054  |
| Ba-PWV at the second visit, cm/s             | 1300 ± 168         | 1271 ± 172         | 1291 ± 171            | 1338 ± 155           | <.001 |
| Ba-PWV at the third visit, cm/s              | 1556 ± 262         | 1477 ± 236         | 1543 ± 241            | 1649 ± 278           | <.001 |
| Ba-PWV change <sup>a</sup> , cm/s            | 256 ± 204          | 206 ± 181          | 251 ± 186             | 311 ± 228            | <.001 |
| Ratio of ba-PWV change <sup>b</sup> , %      | 20.1 ± 15.9        | 16.8 ± 15.0        | 20.0 ± 15.0           | 23.6 ± 17.0          | <.001 |
| Elevated ba-PWV <sup>c</sup> , $n$ (%)       | 501 (35.6)         | 109 (23.3)         | 151 (32.3)            | 240 (51.1)           | <.001 |

Note: Data are baseline characteristics of study participants unless indicated otherwise.

Data are mean ± SD or median (quartile 1-quartile 3) for continuous variables and number (percentage) for categorical variables.

Abbreviations: ba-PWV, brachial-ankle pulse wave velocity; SBP, systolic blood pressure; SD, standard deviation; T, tertial.

<sup>a</sup>Ba-PWV change was calculated by abstracting ba-PWV at the 2nd visit from ba-PWV at the 3rd visit.

<sup>b</sup>Ratio of ba-PWV change was calculated by dividing ba-PWV change by ba-PWV at the 2nd visit.

<sup>c</sup>Elevated ba-PWV was defined as ba-PWV ≥ 1618 cm/s, which was the upper quartile of ba-PWV at the 2nd visit.

\*Average blood pressure was the mean level of blood pressure of the 3 visits.

PP, suggesting that the long-term SBP and PP variabilities may play important roles in the subclinical stage of atherosclerosis in Chinese community adults.

Studies investigating the relationship between visit-to-visit BPV and ba-PWV are rare. Recently, several studies have examined the long-term BPV and found that not only average SBP but also SBP variability is an independent risk factor for atherosclerosis and organ damage in patients with hypertension or other cardiovascular risk factors.<sup>17,28,37,38</sup> Unlike previous studies, our study focused on the association of long-term BPV with subclinical atherosclerosis in the community adults. It should be noted that the study population was a selected sample from the general population because we randomly selected participants with different glycemic status at a 1:1.2:1.44 ratio at the 2nd visit, leading to more participants with diabetes or



FIGURE 2 (A) Ba-PWV changes and the occurrence of an elevated ba-PWV according to tertiles of SBP-SD. (B) Ba-PWV changes and the occurrence of an elevated ba-PWV according to tertiles of DBP-SD. (C) Ba-PWV changes and the occurrence of an elevated ba-PWV according to tertiles of PP-SD

IGR in the selected sample than the general population. The proportion of the population with impaired glucose regulation at baseline increased, which could make the overall baseline FPG level higher than that of the general population. Considering the effect of higher blood glucose itself on blood vessels, the overall ba-PWV may also be higher than that of the general population. Therefore, we have adjusted both the baseline FPG and ba-PWV at the 2nd visit in the regression analysis. Our findings suggested that the long-term SBP and PP variabilities may play important roles in the development of atherosclerosis at an early and subclinical stage, before a clinical CVD event occurred. This has important clinical and public health implications. Regular monitoring of BP levels is recommended and besides BP levels per se, an evaluation of BPV should also be considered in early prevention of subclinical atherosclerosis.

The mechanism connecting visit-to-visit BPV with vascular damage remains uncertain. Kikuya et al. suggested that increased BPV in

elderly and hypertensive patients may be partly due to the increased stiffness and decreased compliance of the large elastic artery caused by aging and hypertension, leading to the decreased function of the pressure reflex.<sup>39</sup> Their study also suggested that disturbed baroreflex function was associated with overpressuring responses to mental and physical stimuli and regulates orthostatic hypotension, postprandial hypotension, and other conditions that lead to increased BPV. Another study suggested that the adverse effects of an increased BPV possibly relate to a greater traumatic effect of wider BP swings on the vessel wall, promoting early target-organ damage.<sup>40</sup> Eto et al. suggested that, independent of average BP, the increase of BPV may contribute to the formation of atherosclerosis in animal models by inhibiting the production of nitric oxide and damaging endothelial function and enhancing the formation of neointima.<sup>41</sup>

Findings from the current study also revealed that compared to individuals with hypertension, individuals without hypertension

807

|                         |                      | Changes of ba-PWV |         |                               |            |  |  |
|-------------------------|----------------------|-------------------|---------|-------------------------------|------------|--|--|
|                         |                      | Ba-PWV change     | (cm/s)  | Ratio of ba-PWV change<br>(%) |            |  |  |
| Measures of variability |                      | β±SE              | p value | β±SE                          | p<br>value |  |  |
| SBP-SD                  | Model 1              | 7.579 ± 0.903     | <.001   | 0.519 ± 0.075                 | <.001      |  |  |
|                         | Model 2              | 7.637 ± 0.942     | <.001   | 0.523 ± 0.076                 | <.001      |  |  |
|                         | <sup>a</sup> Model 3 | 7.307 ± 0.935     | <.001   | $0.505 \pm 0.067$             | <.001      |  |  |
|                         | <sup>d</sup> Model 4 | 5.667 ± 0.930     | <.001   | 0.424 ± 0.072                 | <.001      |  |  |
| DBP-SD                  | Model 1              | 5.990 ± 1.787     | .001    | $0.418 \pm 0.143$             | .003       |  |  |
|                         | Model 2              | 6.166 ± 1.791     | .015    | $0.430 \pm 0.143$             | .018       |  |  |
|                         | <sup>b</sup> Model 3 | 4.260 ± 1.784     | .017    | 0.341 ± 0.144                 | .018       |  |  |
|                         | <sup>e</sup> Model 4 | 3.203 ± 1.733     | .065    | 0.229 ± 0.134                 | .087       |  |  |
| PP-SD                   | Model 1              | 8.574 ± 1.121     | <.001   | 0.584 ± 0.090                 | <.001      |  |  |
|                         | Model 2              | 8.590 ± 1.123     | <.001   | 0.585 ± 0.090                 | <.001      |  |  |
|                         | <sup>c</sup> Model 3 | 8.046 ± 1.131     | <.001   | 0.554 ± 0.091                 | <.001      |  |  |
|                         | <sup>f</sup> Model 4 | 6.159 ± 1.141     | <.001   | 0.461 ± 0.088                 | <.001      |  |  |

TABLE 2Linear regression analysis ofSBP-SD, DBP-SD, and PP-SD associatedwith the changes of ba-PWV

Note: Model 1 was adjusted for age and sex.

Model 2 was additionally adjusted for education, current smoking, current drinking, and physical activity.

Abbreviations: ba-PWV, brachial-ankle pulse wave velocity; DBP, diastolic pressure; FPG, fasting plasma glucose; HR, heart rate; LDL-c, low-density lipoprotein cholesterol;  $\log_{10}$ TG,  $\log_{10}$ -transformed triglycerides; PP, pulse pressure; SBP, systolic blood pressure; SD, the standard deviation; SE, standard error; VVV, visit-to-visit variability; WC, waist circumference;  $\beta$ , regression coefficient.

<sup>a</sup>Model 3 was additionally adjusted for baseline WC, DBP, FPG, log<sub>10</sub>TG, LDL-c, and HR.

<sup>b</sup>Model 3 was additionally adjusted for baseline WC, SBP, FPG, log<sub>10</sub>TG, LDL-c, and HR.

 $^{\rm c}$  Model 3 was additionally adjusted for baseline WC, FPG,  $\log_{10}$  TG, LDL-c, and HR.

<sup>d</sup>Model 4 was additionally adjusted for average SBP and ba-PWV at the 2nd visit.

<sup>e</sup>Model 4 was additionally adjusted for average DBP and ba-PWV at the 2nd visit.

<sup>f</sup>Model 4 was additionally adjusted for average PP and ba-PWV at the 2nd visit.

TABLE 3 Logistic regression analysis of SBP-SD, DBP-SD, and PP-SD as continuous variables and the development of an elevated ba-PWV

|                            | Model 1          |            | Model 2          |            | Model 3                       |            | Model 4                       |            |
|----------------------------|------------------|------------|------------------|------------|-------------------------------|------------|-------------------------------|------------|
| Measures of<br>variability | OR (95% CI)      | p<br>value | OR (95% CI)      | p<br>value | OR (95% CI)                   | p<br>value | OR (95% CI)                   | p<br>value |
| SBP-SD                     | 1.09 (1.07–1.12) | <.001      | 1.09 (1.07–1.12) | <.001      | 1.10 (1.07–1.13) <sup>a</sup> | <.001      | 1.06 (1.03–1.09) <sup>d</sup> | <.001      |
| DBP-SD                     | 1.06 (1.02–1.10) | <.001      | 1.06 (1.02–1.11) | .004       | 1.03 (0.99–1.08) <sup>b</sup> | .193       | 1.03 (0.98–1.07) <sup>e</sup> | .275       |
| PP-SD                      | 1.11 (1.08–1.15) | <.001      | 1.11 (1.08–1.15) | <.001      | 1.11 (1.08–1.14) <sup>c</sup> | <.001      | 1.07 (1.03–1.10) <sup>f</sup> | <.001      |

*Note*: Model 1 was adjusted for age and sex.

Model 2 was additionally adjusted for education, current smoking, current drinking, and physical activity.

Abbreviations: ba-PWV, brachial-ankle pulse wave velocity; CI, confidence internal; DBP, diastolic pressure; FPG, fasting plasma glucose; HR, heart rate; LDL-c, low-density lipoprotein cholesterol; log<sub>10</sub>TG, log<sub>10</sub>-transformed triglycerides; OR, odds ratio; PP, pulse pressure; SBP, systolic blood pressure; SD, the standard deviation; VVV, visit-to-visit variability; WC, waist circumference.

<sup>a</sup>Model 3 was additionally adjusted for baseline WC, DBP, FPG, log<sub>10</sub>TG, LDL-c, and HR.

<sup>b</sup>Model 3 was additionally adjusted for baseline WC, SBP, FPG, log<sub>10</sub>TG, LDL-c, and HR.

<sup>c</sup>Model 3 was additionally adjusted for baseline WC, FPG, log<sub>10</sub>TG, LDL-c, and HR.

<sup>d</sup>Model 4 was additionally adjusted for average SBP.

<sup>e</sup>Model 4 was additionally adjusted for average DBP.

<sup>f</sup>Model 4 was additionally adjusted for average PP.

TABLE 4 Logistic regression analysis of VVV in SBP-SD, DBP-SD, and PP-SD as categorical variables and the development of an elevated ba-PWV

|                         | OR (95% CI)      |                  |                               |                               |  |  |
|-------------------------|------------------|------------------|-------------------------------|-------------------------------|--|--|
| Measures of variability | Model 1          | Model 2          | Model 3                       | Model 4                       |  |  |
| SBP-SD                  |                  |                  |                               |                               |  |  |
| T1                      | Reference        | Reference        | Reference                     | Reference                     |  |  |
| T2                      | 1.52 (1.12–2.07) | 1.53 (1.12–2.09) | 1.62 (1.17–2.24) <sup>a</sup> | 1.36 (0.96–1.91) <sup>d</sup> |  |  |
| Т3                      | 2.97 (2.20-4.01) | 2.98 (2.21-4.03) | 3.27 (2.37-4.50) <sup>a</sup> | 2.22 (1.57–3.12) <sup>d</sup> |  |  |
| DBP-SD                  |                  |                  |                               |                               |  |  |
| T1                      | Reference        | Reference        | Reference                     | Reference                     |  |  |
| T2                      | 1.53 (1.15–2.05) | 1.54 (1.15–2.06) | 1.49 (1.09–2.03) <sup>b</sup> | 1.51 (1.10-2.06) <sup>e</sup> |  |  |
| Т3                      | 1.39 (1.04-1.86) | 1.40 (1.04–1.88) | 1.11 (0.81–1.53) <sup>b</sup> | 1.11 (0.81–1.53) <sup>e</sup> |  |  |
| PP-SD                   |                  |                  |                               |                               |  |  |
| T1                      | Reference        | Reference        | Reference                     | Reference                     |  |  |
| T2                      | 1.49 (1.09-2.03) | 1.50 (1.10-2.04) | 1.50 (1.09–2.06) <sup>c</sup> | 1.54 (1.10–2.14) <sup>f</sup> |  |  |
| Т3                      | 2.88 (2.13-3.89) | 2.90 (2.14-3.92) | 2.80 (2.05-3.82) <sup>c</sup> | 1.92 (1.38–2.68) <sup>f</sup> |  |  |

Note: Model 1 was adjusted for age and sex.

Model 2 was additionally adjusted for education, current smoking, current drinking, and physical activity.

Abbreviations: ba-PWV, brachial-ankle pulse wave velocity; CI, confidence internal; DBP, diastolic pressure; FPG, fasting plasma glucose; HR, heart rate; LDL-c, low-density lipoprotein cholesterol; log<sub>10</sub>TG, log<sub>10</sub>-transformed triglycerides; OR, odds ratio; PP, pulse pressure; SBP, systolic blood pressure; SD, the standard deviation; VVV, visit-to-visit variability.

<sup>a</sup>Model 3 was additionally adjusted for baseline WC, DBP, FPG, log<sub>10</sub>TG, LDL-c, and HR.

<sup>b</sup>Model 3 was additionally adjusted for baseline WC, SBP, FPG, log<sub>10</sub>TG, LDL-c, and HR.

<sup>c</sup>Model 3 was additionally adjusted for baseline WC, FPG, log<sub>10</sub>TG, LDL-c, and HR.

<sup>d</sup>Model 4 was additionally adjusted for average SBP.

<sup>e</sup>Model 4 was additionally adjusted for average DBP.

<sup>f</sup>Model 4 was additionally adjusted for average PP.

were particularly susceptible to the impact of long-term BPV. One possible explanation is that individuals without hypertension, often with fewer vascular risk factors, are more sensitive to BPV and that, with hypertension, perhaps other risk factors might overshadow the negative influence of BPV. Another possible explanation is that individuals without hypertension, often with lower blood pressure, are more vulnerable to blood pressure variability<sup>42</sup> and that, with higher blood pressure, the contribution of variability is less pronounced.<sup>1.17</sup>

To the best of our knowledge, studies on the association between visit-to-visit BPV and arterial stiffness in the community adults are rare. In addition, because antihypertensive drugs could delay the development of atherosclerosis<sup>43</sup> and interfere with BPV,<sup>44</sup> we excluded individuals with antihypertensive drugs at any of the 3 visits in the current analysis. The current study has several limitations. The long-term BPV was calculated using BP levels at the 3 visits, and ba-PWV was assessed at the 2nd and the 3rd visits. Because BP varies a great deal even in a short period of time, using BP measurements in 1-day time to represent BP levels around one visit could be inaccurate to some extent. Multiple BP measurements over several days around each visit could have provided a more accurate evaluation of the long-term BP variability. A ba-PWV measurement at the baseline visit and a prospective analysis with the assessment of ba-PWV changes after the 3rd visit are needed to better elucidate the potential causal relationship between BPV and arterial stiffness. In addition, the study participants were middle-aged and elderly community residents recruited from suburban Shanghai; therefore, findings from the current study may not be generalizable to people within other age groups or with different socioeconomic or lifestyle background.

# 5 | CONCLUSIONS

Our findings suggest that a greater visit-to-visit BPV is significantly associated with an increased arterial stiffness, above and beyond the effect of mean BP in the community adults. These findings add to the growing body of evidence on the prognostic value of longterm BPV and highlight the importance of stable BP control in a long term. More prospective studies are needed to further demonstrate

FIGURE 3 (A) Association of SBP-SD with elevated ba-PWV in different subgroups of participants. (B) Association of DBP-SD with elevated ba-PWV in different subgroups of participants. (C) Association of PP-SD with elevated ba-PWV in different subgroups of participants. All models are adjusted for potential confounding factors including age, sex, education, current smoking, current drinking, physical activity, baseline WC, DBP/SBP/-, FPG, log<sub>10</sub>TG, LDL-c, HR, and average SBP/DBP/PP

|                          | Number of participants |                 | Odds ratio (95% CI) | P for interaction  |
|--------------------------|------------------------|-----------------|---------------------|--------------------|
| (A)                      |                        |                 |                     |                    |
| Age (years)              |                        |                 |                     | 0.749              |
| < 60                     | 1096                   |                 | 1.05 (1.02-1.09)    |                    |
| Sex                      | 311                    |                 | 1.08 (1.02-1.14)    | 0.011              |
| Male                     | 511                    |                 | 1 02 (0 97-1 06)    | 0.011              |
| Female                   | 896                    |                 | 1.09 (1.05-1.12)    |                    |
| BMI (kg/m <sup>2</sup> ) |                        |                 |                     | 0.159              |
| < 25                     | 770                    |                 | 1.09 (1.04-1.13)    |                    |
| ≥ 25                     | 637                    |                 | 1.03 (1.00-1.07)    |                    |
| Smoking status           | 1014                   |                 | 1.06 (1.02, 1.10)   | 0.843              |
| Yes                      | 363                    |                 | 1.05 (0.99-1.11)    |                    |
| Drinking status          |                        |                 |                     | 0.780              |
| No                       | 1174                   | <b>⊢</b> ∎→     | 1.06 (1.03-1.09)    |                    |
| Yes                      | 233                    |                 | 1.09 (1.01-1.17)    |                    |
| Diabetes                 |                        |                 |                     | 0.046              |
| No                       | 1041                   |                 | 1.07 (1.04-1.11)    |                    |
| Hypertension             | 300                    |                 | 1.01 (0.95-1.07)    | 0.003              |
| No                       | 1164                   |                 | 1.08 (1.04-1.11)    | 0.003              |
| Yes                      | 243                    |                 | 1.00 (0.96-1.05)    |                    |
|                          | ·                      |                 |                     |                    |
|                          | 0.9                    | 1.0 1.1 1.2     |                     |                    |
| (B)                      | Number of participants |                 | Odds ratio (95% CI) | P for interaction  |
| . ,                      |                        |                 |                     |                    |
| Age (years)              |                        | 1               |                     | 0.538              |
| < 60                     | 1096                   | <b>⊢</b>        | 1.03 (0.98-1.08)    |                    |
| ≥ 60                     | 311                    |                 | 1.00 (0.91-1.10)    |                    |
| Sex                      |                        |                 |                     | 0.177              |
| Male                     | 511                    |                 | 0.99 (0.92-1.07)    |                    |
| $BMI (kg/m^2)$           | 000                    |                 | 1.04 (0.00 1.10)    | 0.471              |
| < 25                     | 770                    | <b></b>         | 1.03 (0.97-1.10)    | 0.112              |
| ≥ 25                     | 637                    |                 | 1.00 (0.95-1.06)    |                    |
| Smoking status           |                        |                 |                     | 0.889              |
| No                       | 1044                   | <b>⊢</b>        | 1.02 (0.97-1.07)    |                    |
| Yes                      | 363                    |                 | 1.03 (0.94-1.12)    | 0.444              |
| Drinking status          | 1174                   |                 | 1.01 (0.06, 1.06)   | 0.444              |
| Yes                      | 233                    |                 | 1.07 (0.96-1.19)    |                    |
| Diabetes                 |                        |                 |                     | 0.633              |
| No                       | 1041                   | <b>⊢</b>        | 1.02 (0.98-1.08)    |                    |
| Yes                      | 366                    | ·               | 1.06 (0.96-1.19)    |                    |
| Hypertension             |                        |                 |                     | 0.043              |
| No                       | 1164                   |                 | 1.06 (1.00-1.12)    |                    |
| Tes                      | 243                    |                 | 0.90 (0.90-1.04)    |                    |
|                          | 0.8                    | 0.9 1.0 1.1 1.2 |                     |                    |
|                          | Number of participants |                 | Odds ratio (95% CI) | P for interaction  |
| (C)                      | Number of participants |                 | Ouus 1810 (95% CI)  | F IOI IIIteraction |
| Age (vears)              |                        |                 |                     | 0.451              |
| < 60                     | 1096                   |                 | 1 06 (1 03-1 10)    | 0.451              |
| ≥ 60                     | 311                    |                 | 1.05 (1.00-1.12)    |                    |
| Sex                      |                        |                 |                     | 0.141              |
| Male                     | 511                    | <b>→</b>        | 1.04 (0.99-1.09)    |                    |
| Female                   | 896                    |                 | 1.09 (1.04-1.13)    |                    |
| BMI (kg/m²)              | 770                    |                 | 1 10 (1 05 1 10)    | 0.028              |
| < 25<br>≥ 25             | 637                    |                 | 1.03 (0.99-1.08)    |                    |
| Smoking status           |                        |                 |                     | 0.633              |
| No                       | 1044                   |                 | 1.06 (1.03-1.10)    |                    |
| Yes                      | 363                    |                 | 1.07 (1.01-1.14)    |                    |
| Drinking status          |                        |                 |                     | 0.655              |
| No                       | 1174                   |                 | 1.06 (1.03-1.10)    |                    |
| Yes                      | 233                    |                 | 1.11 (1.02-1.20)    | 0.420              |
| Mo                       | 10/11                  |                 | 1 07 (1 02 1 10)    | 0.430              |
| Yes                      | 366                    |                 | 1.05 (0.98-1.12)    |                    |
| Hypertension             |                        |                 | ,                   | 0.001              |
| No                       | 1164                   | ·•              | 1.09 (1.05-1.14)    |                    |
| Yes                      | 243                    |                 | 1.02 (0.97-1.06)    |                    |
|                          | 0.9                    | 1.0 1.1 1.2     |                     |                    |

the importance of the long-term BPV in the development of early cardiovascular diseases in diverse populations.

### ACKNOWLEDGEMENTS

The authors would like to thank all the fieldworkers for their contribution to the study and the participants for their cooperation.

### CONFLICT OF INTEREST

The authors have no conflicts of interest to declare.

### AUTHOR CONTRIBUTIONS

YZ, LB, YX, and YC had access to all data and take responsibility for its integrity and analysis. YZ and YX conceived the hypotheses and analyses. YZ drafted the paper. YZ and LB provided statistical analysis. YZ, LB, and JZ collected the data. YX and YC revised the manuscript. ML, TW, MX, JL, SW, YB, WW, and GN refined interpretation and the final manuscript. All authors were involved in writing the paper and had final approval of the submitted and published versions.

### ORCID

Yuwen Zhang <sup>(1)</sup> https://orcid.org/0000-0001-5311-2426 Yuhong Chen <sup>(1)</sup> https://orcid.org/0000-0002-6506-2283

### REFERENCES

- Lewington SCR, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*. 2002;360(9349):1903-1913.
- Psaty BM, Furberg CD, Kuller LH, et al. Association between blood pressure level and the risk of myocardial infarction, stroke, and total mortality: the cardiovascular health study. *Arch Intern Med.* 2001;161(9):1183-1192.
- Staessen J. Risks of untreated and treated isolated systolic hypertension in the elderly: meta analysis of outcome trial. *Lancet*. 2000;355(9207):865-872.
- Lenfant C, Chobanian AV, Jones DW, Roccella EJ. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). *Circulation*. 2003;107(24):2993-2994. https://doi.org/10.1161/01. Cir.000080481.62058.03
- Gao S, Hendrie HC, Wang C, et al. Redefined blood pressure variability measure and its association with mortality in elderly primary care patients. *Hypertension*. 2014;64(1):45-52.
- Poortvliet RKE, Ford I, Lloyd SM, et al. Blood pressure variability and cardiovascular risk in the PROspective study of pravastatin in the elderly at risk (PROSPER). *PLoS One*. 2012;7(12):e52438.
- Shimbo D, Newman JD, Aragaki AK, et al. Association between annual visit-to-visit blood pressure variability and stroke in postmenopausal women: data from the women's health initiative. *Hypertension*. 2012;60(3):625-630.
- Grassi G, Bombelli M, Brambilla G, Trevano FQ, Dell'Oro R, Mancia G. Total cardiovascular risk, blood pressure variability and adrenergic overdrive in hypertension: evidence, mechanisms and clinical implications. *Curr Hypertens Rep.* 2012;14(4):333-338.
- Hastie CEJP, Coleman H, McCallum L, et al. Long-term and ultra long-term blood pressure variability during follow-up and mortality in 14 522 patients with hypertension. *Hypertension*. 2013;62(4):698-705.

- Hsieh YTTS, Cho TJ, Chang SJ, Chen JF, Hsieh MC. Visit-to-visit variability in blood pressure strongly predicts all-cause mortality in patients with type 2 diabetes: a 5-5-year prospective analysis. *Eur J Clin Invest*. 2012;42(3):245-253.
- Muntner P, Shimbo D, Tonelli M, Reynolds K, Arnett DK, Oparil S. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. *Hypertension*. 2011;57(2):160-166.
- 12. Muntner P, Whittle J, Lynch AI, et al. Visit-to-visit variability of blood pressure and coronary heart disease, stroke, heart failure, and mortality. *Ann Intern Med.* 2015;163(5):329.
- Stevens SL, Wood S, Koshiaris C, et al. Blood pressure variability and cardiovascular disease: systematic review and meta-analysis. *BMJ*. 2016;9(354):i4098.
- 14. Suchy-Dicey AM, Wallace ER, Elkind MS, et al. Blood pressure variability and the risk of all-cause mortality, incident myocardial infarction, and incident stroke in the cardiovascular health study. *Am J Hypertens*. 2013;26(10):1210-1217.
- Tai C, Sun Y, Dai N, et al. Prognostic significance of visit-to-visit systolic blood pressure variability: a meta-analysis of 77,299 patients. *J Clin Hypertens*. 2015;17(2):107-115.
- Wang J, Shi X, Ma C, et al. Visit-to-visit blood pressure variability is a risk factor for all-cause mortality and cardiovascular disease. J Hypertens. 2017;35(1):10-17.
- Pm R. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. *Lancet*. 2010;375(9718):895-905.
- Parati G, Ochoa JE, Lombardi C, Bilo G. Blood pressure variability: assessment, predictive value, and potential as a therapeutic target. *Curr Hypertens Rep.* 2015;17(4):23.
- Brickman AMRC, Luchsinger JA. Long-term blood pressure fluctuation and cerebrovascular disease in an elderly cohort. Arch Neurol. 2010;2010(67):564-569. https://doi.org/10.1016/j. ycar.2011.01.060
- Nagai M, Hoshide S, Ishikawa J, Shimada K, Kario K. Visit-to-visit blood pressure variations: new independent determinants for cognitive function in the elderly at high risk of cardiovascular disease. J Hypertens. 2012;30(8):1556-1563.
- Shimbo D, Shea S, McClelland RL, et al. Associations of aortic distensibility and arterial elasticity with long-term visit-to-visit blood pressure variability: the multi-ethnic study of atherosclerosis (MESA). Am J Hypertens. 2013;26(7):896-902.
- 22. Kilpatrick ES, Rigby AS, Atkin SL. The role of blood pressure variability in the development of nephropathy in type 1 diabetes. *Diabetes Care.* 2010;33(11):2442-2447.
- Wu Z, Jin C, Vaidya A, et al. Longitudinal patterns of blood pressure, incident cardiovascular events, and all-cause mortality in normotensive diabetic peoplenovelty and significance. *Hypertension*. 2016;68(1):71-77.
- Yu ZB, Li D, Chen XY, et al. Association of visit-to-visit variability of blood pressure with cardiovascular disease among type 2 diabetes mellitus patients: a cohort study. *Diabetes Metab J.* 2019;43(3):350-367. https://doi.org/10.4093/dmj.2018.0108
- 25. Lau K-K, Wong Y-K, Teo K-C, et al. Long-term prognostic implications of visit-to-visit blood pressure variability in patients with ischemic stroke. *Am J Hypertens*. 2014;27(12):1486-1494.
- Mezue K, Goyal A, Pressman GS, Horrow JC, Rangaswami J. Blood pressure variability predicts adverse events and cardiovascular outcomes in chronic kidney disease: a post-hoc analysis of the SPRINT trial. Am J Hypertens. 2018;31(1):48-52. https://doi.org/10.1093/ ajh/hpx128
- Mehlum MH, Liestol K, Kjeldsen SE, et al. Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. *Eur Heart J.* 2018;39(24):2243-2251. https://doi.org/10.1093/eurheartj/ehx760

### 

- Nagai M, Dote K, Kato M, et al. Visit-to-visit blood pressure variability, average BP level and carotid arterial stiffness in the elderly: a prospective study. J Hum Hypertens. 2017;31(4):292-298. https:// doi.org/10.1038/jhh.2016.77
- Wang Y, Yang Y, Wang A, et al. Association of long-term blood pressure variability and brachial-ankle pulse wave velocity: a retrospective study from the APAC cohort. *Sci Rep.* 2016;6:21303. https://doi.org/10.1038/srep21303
- Ning G, Bi Y, Wang T, et al. Relationship of urinary Bisphenol A concentration to risk for prevalent type 2 diabetes in Chinese adults. *Ann Intern Med.* 2011;155(6):368.
- Wang T, Lu J, Xu Y, et al. Circulating prolactin associates with diabetes and impaired glucose regulation: a population-based study. Diabetes Care. 2013;36(7):1974-1980. https://doi.org/10.2337/ dc12-1893
- Lee P, Macfarlane D, Lam T, Stewart S. Validity of the international physical activity questionnaire short form (IPAQ-SF): a systematic review. Int J Behav Nutr Phys Act. 2011;8(1):115.
- Paul M, Jeff W, Lynch AI, et al. Visit-to-visit variability of blood pressure and coronary heart disease, stroke, heart failure, and mortality: a cohort study. *Ann Intern Med.* 2015;163(5):329.
- Bangalore S, Fayyad R, Laskey R, Demicco DA, Messerli FH, Waters DD. Body-weight fluctuations and outcomes in coronary disease. N Engl J Med. 2017;376(14):1332-1340.
- Echouffo-Tcheugui JB, Zhao S, Brock G, Matsouaka RA, Kline D, Joseph JJ. Visit-to-visit glycemic variability and risks of cardiovascular events and all-cause mortality: the ALLHAT study. *Diabetes Care*. 2019;42(3):486-493. https://doi.org/10.2337/dc18-1430
- Lin L, Peng K, Du R, et al. High glomerular filtration rate is associated with arterial stiffness in Chinese population. J Hypertens. 2017;35(2):385-391. https://doi.org/10.1097/HJH.0000000000 001158
- Tatasciore A, Renda G, Zimarino M, et al. Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. *Hypertension*. 2007;50(2):325-332.
- Okada H, Fukui M, Tanaka M, et al. Visit-to-visit variability in systolic blood pressure is correlated with diabetic nephropathy and

atherosclerosis in patients with type 2 diabetes. *Atherosclerosis*. 2012;220(1):155-159.

- Kikuya MHA, Ohokubo T, Tsuji I, et al. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. *Hypertension*. 2000;36(5):901-906.
- 40. Warlow C, Sudlow C, Dennis M, Wardlaw J, Sandercock P. Stroke. Lancet. 2003;362(9391):1211-1224.
- 41. Masato E, Kenji T, Masahiro A, et al. Reduced endothelial vasomotor function and enhanced neointimal formation after vascular injury in a rat model of blood pressure lability. *Hypertens Res.* 2003;26(12):991-998.
- 42. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. *Lancet.* 2010;375:938-948.
- Wu AYT, Low LP. Managing vascular risk in hypertension with a focus on microalbuminuria: attitude and practices. *Singapore Med J*. 2009;50(10):976-981.
- Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. *Lancet*. 2010;375(9718):906-915.

### SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Zhang Y, Bie L, Li M, et al. Visit-to-visit blood pressure variability is associated with arterial stiffness in Chinese adults: A prospective analysis. *J Clin Hypertens*. 2021;23:802–812. https://doi.org/10.1111/jch.14166